A Phase II Trial of In Vivo Gene Therapy With the Herpes Simplex Thymidine Kinase for the Treatment of Ovarian Cancer
- Determine the efficacy and safety of in vivo gene therapy with herpes simplex thymidine
kinase (HSVtk) vector producer cells (VPC) followed by ganciclovir in women with
refractory or relapsed ovarian epithelial adenocarcinoma, fallopian tube cancer, or
- Determine any development of systemic immunity to this regimen or tumor in these
- Determine the toxic effects of intraperitoneal HSVtk VPC in these patients.
OUTLINE: All patients receive an intraperitoneal catheter prior to infusion.
Patients receive herpes simplex thymidine kinase (HSVtk) vector producer cells (VPC) IP over
15-60 minutes on day 0, followed by ganciclovir IV 2 times daily on days 28-41. Treatment
repeats for up to 3 courses in patients with stable or responsive disease.
Patients are followed every 3 months for 1 year.
PROJECTED ACCRUAL: A total of 14-20 patients will be accrued for this study within 18-24
Primary Purpose: Treatment
Charles Joseph Link, MD
John Stoddard Cancer Center at Iowa Methodist Medical Center
United States: Federal Government
|Human Gene Therapy Research Institute||Des Moines, Iowa 50309|